IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$40.32 USD
-0.18 (-0.44%)
Updated May 20, 2024 04:00 PM ET
After-Market: $40.36 +0.04 (0.10%) 7:40 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
IDEAYA Biosciences, Inc. [IDYA]
Reports for Purchase
Showing records 61 - 80 ( 167 total )
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Early Activity for IDE397; Darovasertib/Crizotinib Data in Q4:21
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Update - Daro + Crizotinib Data Expected by YE & More 2022 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Busy 2H:21 Ahead Across Precision Oncology Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Update - The Stock Has Rallied, But Still More to Come During 2H2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Strong Balance Sheet; IDE397 Phase 1 Data Expected 4Q21; Lowering PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Ideaya Highlights Clinical Progress and Reaffirms Readouts for 2H2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IDE397 Pharmacodynamics Update; Promising Darovasertib Combination Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IDE397 Already on Target; Darovasertib Combos Update
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; Darovasertib Pathway to Approval Expected to Become More Clear in 2H21; Lowering PT by $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Darovasertib Crizotinib Combination Shows Early Promise
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Update- Key Readouts Expected During 2H21. Reiterate Buy, $38 PT
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z